| Systematic (IUPAC) name | |
|---|---|
| (RS)-3-ethyl-3-methyl-pyrrolidine-2,5-dione | |
| Clinical data | |
| Trade names | Zarontin |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a682327 |
| Pregnancy cat. | D (Australia, United States) |
| Legal status | ℞-only (U.S.) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 93%[1] |
| Metabolism | Hepatic (CYP3A4, CYP2E1) |
| Half-life | 53 hours |
| Excretion | Renal (20%) |
| Identifiers | |
| CAS number | 77-67-8 |
| ATC code | N03AD01 |
| PubChem | CID 3291 |
| DrugBank | APRD00318 |
| ChemSpider | 3175 |
| UNII | 5SEH9X1D1D |
| KEGG | D00539 |
| ChEBI | CHEBI:4887 |
| ChEMBL | CHEMBL696 |
| Chemical data | |
| Formula | C7H11NO2 |
| Mol. mass | 141.168 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Ethosuximide is a succinimide anticonvulsant, used mainly in absence seizures.
Contents |
It is approved for absence seizures.[2] Ethosuximide is considered the first choice drug for treating absence seizures in part because it lacks the idiosyncratic hepatotoxicity of the alternative anti-absence drug, valproic acid.[3]
It was reported to have been used for intermittent explosive disorder in 1980 by Drs Andrulonis, Donnelly, Glueck, Stroebel, and Szabek.[4]
Therapeutic drug concentrations are individualized according to response and tolerance. Common Serum Therapeutic Range: 40-100 µg/mL. Potentially Toxic Serum Concentration: >100 µg/mL.
Ethosuximide is marketed under the trade names Emeside and Zarontin. However, both capsule preparations were discontinued from production, leaving only generic preparations available. Emeside capsules were discontinued by their manufacturer, Laboratories for Applied Biology, in 2005.[1] Similarly, Zarontin capsules were discontinued by Pfizer in 2007.[2] Syrup preparations of both brands are still available.
There is some controversy over the exact mechanism by which ethosuximide prevents absence seizures. While the view that ethosuximide is a T-type calcium channel blocker gained widespread support following its proposal, attempts to replicate the initial finding were inconsistent.
In March 1989, Coulter, Huguenard and Prince showed that ethosuximide and dimethadione, both effective anti-absence agents, reduced low-threshold Ca2+ currents in T-type Ca2+ channels in freshly removed thalamic neurons.[5] In June of that same year, they also found the mechanism of this reduction to be voltage-dependent, using acutely neurons of rats and guinea pigs; it was also noted that valproic acid, which is also used in absence seizures, did not do that.[6] The next year, they showed that anticonvulsant succinimides did this and that the proconvulsant ones did not.[7] The first part was supported by Kostyuk et al. in 1992, who reported a substantial reduction in current in dorsal root ganglia at concentrations ranging from 7 µmol/L to 1 mmol/L.[8]
That same year, however, Herrington and Lingle found no such effect at concentrations of up to 2.5 mmol/L.[9] The year after, a study conducted on human neocortical cells removed during surgery for intractable epilepsy, the first to use human tissue, found that ethosuximide had no effect on Ca2+ currents at the concentrations typically needed for a therapeutic effect.[10]
In 1998, Slobodan M. Todorovic and Christopher J. Lingle of Washington University reported a 100% block of T-type current in dorsal root ganglia at 23.7 ± 0.5 mmol/L, far higher than Kostyuk reported.[11] That same year, Leresche et al. reported that ethosuximide had no effect on T-type currents, but did decrease noninactivating Na+ current by 60% and the Ca2+-activated K+ currents by 39.1 ± 6.4% in rat and cat thalamocortical cells. It was concluded that the decrease in Na+ current is responsible for the anti-absence properties.[12]
In the introduction of a paper published in 2001, Dr. Juan Carlos Gomora and colleagues at the University of Virginia in Charlottesville pointed out that past studies were often done in isolated neurons that had lost most of their T-type channels.[13] Using cloned α1G, α1H, and α1I T-type calcium channels, Gomora's team found that ethosuximide blocked the channels with an IC50 of 12 ± 2 mmol/L and that of N-desmethylmethsuximide (the active metabolite of mesuximide) is 1.95 ± 0.19 mmol/L for α1G, 1.82 ± 0.16 mmol/L for α1I, and 3.0 ± 0.3 mmol/L for α1H. It was suggested that the blockade of open channels is facilitated by ethosuximide's physically plugging the channels when current flows inward.
The following can occur with or without bone marrow loss:
Valproates can either decrease or increase the levels of ethosuximide; However, combinations of valproates and ethosuximide had a greater Protective Index than either drug alone.[14]
It may elevate serum phenytoin levels.
Ethosuximide, 3-ethyl-3-methypyrrolidine-2,5-dione is synthesized from methylethylketone and cyanoacetic ester, which undergo a Knoevenagel condensation. Then hydrogen cyanide is added. After acidic hydrolysis and decarboxylation of the synthesized dinitrile, 2-methyl-2-ethylsuccinic acid is formed. Reacting this product with ammonia gives the diammonium salt, and heterocyclization into ethosuximide takes place during subsequent heating.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||